ClinicalTrials.gg
CompletedNCT06662539ZUPREMEUpdated Mar 23, 2026

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

A Phase 2 interventional study of Petrelintide and Placebo in Obesity, sponsored by Zealand Pharma. Completed at 32 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Zealand Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

Read the detailed description

Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management.

This is a randomized, double-blind, placebo-controlled, parallel-group, multinational, multicenter, dose-finding, Phase 2 clinical trial. The trial will compare 5 doses of once-weekly (OW) subcutaneously administered petrelintide with placebo.

This study consists of 3 periods:

  1. A screening period of 2-3 weeks
  2. A treatment period of 42 weeks
  3. A safety follow-up period of 9 weeks.
02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Weight management
  • Amylin analog
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 493 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants having (BMI) ≥30.0 kg/m2 or BMI ≥27.0 kg/m2 with the presence of at least one of the following comorbidities: hypertension or dyslipidemia (treated or untreated).
  • A female participant is eligible to participate if she is:

    • A woman of nonchildbearing potential. OR
    • A woman of (WOCBP) who is not pregnant, does not intend to be pregnant, not lactating and is willing to use highly effective methods (as required by local regulation or practice) throughout the trial and for 10 weeks after the last injection of the medicinal product (IMP).
  • Ability to comply with the protocol requirements including self-administration of IMP with vial and syringe.

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) ≥48 mmol/mol (6.5%), as measured at screening.
  • History of type 1 or type 2 diabetes mellitus.
  • Treatment with glucose lowering agent(s) within 90 days prior to screening.
  • A self-reported change in body weight >5% within 90 days prior to screening.
  • Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 6 months prior to screening.
  • Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g. sleeve, banding or similar) that have been removed more than 6 months prior to screening, are allowed.
  • Uncontrolled thyroid disease defined as thyroid stimulating hormone >4.20 mIU/L or \<0.27 mIU/L as measured by the central laboratory at screening.
  • Lifetime history of a suicidal attempt.
  • History of major depressive disorder or other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder).
  • Estimated value \<60.0 mL/min/1.73m2, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) Creatinine Equation17, measured at screening.
  • Impaired liver function, defined as and/or aspartate aminotransferase ≥2.0 times or >1.5 times upper normal limit, measured at screening.
  • Presence or history of acute or chronic pancreatitis.
  • Known gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronic treatment that affects gastrointestinal (GI) motility.
  • Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, , stroke, cardiac decompensation.
  • Presence or history of clinically significant arrhythmias or clinically significant conduction disorders.
  • Known or suspected to amylin analogs or related products.
  • History of malignant neoplasms (except for basal or squamous cell skin cancer) within 5 years prior to screening.
  • Known or suspected abuse of alcohol or recreational drugs.
  • Participant previously treated with petrelintide or any other amylin analog.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Petrelintide Dose 1

    Participants will self-inject petrelintide dose 1 subcutaneously once a week.

    Drug: Petrelintide

  • Experimental
    Petrelintide Dose 2

    Participants will self-inject petrelintide dose 2 subcutaneously once a week.

    Drug: Petrelintide

  • Experimental
    Petrelintide Dose 3

    Participants will self-inject petrelintide dose 3 subcutaneously once a week.

    Drug: Petrelintide

  • Experimental
    Petrelintide Dose 4

    Participants will self-inject petrelintide dose 4 subcutaneously once a week.

    Drug: Petrelintide

  • Experimental
    Petrelintide Dose 5

    Participants will self-inject petrelintide dose 5 subcutaneously once a week.

    Drug: Petrelintide

  • Placebo comparator
    Placebo

    Participants will self-inject matching placebo to petrelintide subcutaneously once a week.

    Drug: Placebo

Interventions

  • Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

    Also known as: ZP8396

  • DrugPlacebo

    Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight to Week 28

    To compare the dose-response of increasing doses of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity after 28 weeks of exposure.

    Time frame: From Baseline (Day 1) to Week 28

Secondary outcomes

  1. Percentage of Participants achieving ≥5% Body Weight Loss at Weeks 28 and 42

    To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Weeks 28 and 42

  2. Percentage of Participants achieving ≥10% Body Weight Loss at Weeks 28 and 42

    To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Weeks 28 and 42

  3. Change from baseline in body weight to Weeks 28 and 42

    To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Weeks 28 and 42

  4. Change from baseline in waist circumference to Weeks 28 and 42

    To compare the efficacy of petrelintide versus placebo on waist circumference, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Weeks 28 and 42

  5. Percent change from baseline in body weight to Week 42

    To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 42

  6. Change from baseline in hemoglobin A1c (HbA1c) to Week 42

    To compare the efficacy of petrelintide versus placebo on HbA1c, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 42

  7. Change from baseline in fasting glucose to Week 42

    To compare the efficacy of petrelintide versus placebo on fasting glucose, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 42

  8. Change from baseline in high-sensitivity C-reactive protein (hsCRP) to Week 42

    To compare the efficacy of petrelintide versus placebo on hsCRP, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 42

  9. Change from baseline in fasting lipids to Week 42

    To compare the efficacy of petrelintide versus placebo on fasting lipids, when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 42

  10. Number of treatment emergent adverse events (TEAEs)

    To compare the safety and tolerability of petrelintide versus placebo when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 51

  11. Occurrences of anti-drug antibodies (ADAs) to petrelintide

    To compare the safety and tolerability of petrelintide versus placebo when added as an adjunct to a reduced-calorie diet and increased physical activity.

    Time frame: From Baseline (Day 1) to Week 51

07

Study locations

32 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • Century Research LLC
    Miami, Florida 33155, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060-6977, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Great Lakes Clinical Trials LLC dba Flourish Research
    Chicago, Illinois 60640, United States
  • AMR Wichita East
    Wichita, Kansas 67226, United States
  • Alliance For Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
  • CHEAR Center LLC
    The Bronx, New York 10455, United States
  • Javara Inc
    Charlotte, North Carolina 28210, United States
  • PharmQuest Life Sciences, LLC
    Greensboro, North Carolina 27408, United States
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
  • AMR Norman
    Norman, Oklahoma 73069, United States
  • Altoona Center for Clinical Research - Research
    Duncansville, Pennsylvania 16635, United States
  • Alliance for Multispecialty Research
    Knoxville, Tennessee 37909, United States
  • Clinical Trials of Texas, LLC., dba Flourish Research
    San Antonio, Texas 78229, United States
  • Manaasas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Krakowskie Centrum MedyczneSp.z o.o
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • ETG Siedlce
    Siedlce, Masovian Voivodeship 08-110, Poland
  • FutureMeds Warszawa Centrum
    Warsaw, Masovian Voivodeship 00-215, Poland
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji
    Warsaw, Masovian Voivodeship 02-507, Poland
  • ETG Warszawa
    Warsaw, Masovian Voivodeship 02-677, Poland
  • FutureMeds Targowek
    Warsaw, Masovian Voivodeship 03-291, Poland
  • Futuremeds Olsztyn
    Olsztyn, Warmian-Masurian Voivodeship 10-165, Poland
  • Top Diabet
    Craiova, Dolj 200515, Romania
  • Institutul National de Endocrinologie C I Parhon
    Bucharest, 011863, Romania
  • Institutul Clinic Fundeni
    Bucharest, 022328, Romania
  • Fundatia Dr Victor Babes
    Bucharest, 030303, Romania
  • Institutul De Pneumoftiziologie Marius Nasta
    Bucharest, 050159, Romania
  • Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta
    Constanța, 900591, Romania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Sep 2025, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 29, 2024
StartActual
Dec 9, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Mar 7, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06662539
Lead sponsor
Zealand Pharma
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Dec 9, 2024
Primary completion
Sep 30, 2025
Completion
Mar 7, 2026
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petrelintide

Start the discussion